Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro.

Korda├č T, Weber CEM, Eisel D, Pane AA, Osen W, Eichm├╝ller SB.

Oncotarget. 2018 Aug 21;9(65):32507-32522. doi: 10.18632/oncotarget.25986. eCollection 2018 Aug 21.

2.

Computational Approaches to Prioritize Cancer Driver Missense Mutations.

Zhao F, Zheng L, Goncearenco A, Panchenko AR, Li M.

Int J Mol Sci. 2018 Jul 20;19(7). pii: E2113. doi: 10.3390/ijms19072113. Review.

3.

Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.

Araiza-Olivera D, Feng Y, Semenova G, Prudnikova TY, Rhodes J, Chernoff J.

Oncogene. 2018 Feb 15;37(7):944-952. doi: 10.1038/onc.2017.400. Epub 2017 Oct 23.

4.

p190RhoGAP proteins contain pseudoGTPase domains.

Stiegler AL, Boggon TJ.

Nat Commun. 2017 Sep 11;8(1):506. doi: 10.1038/s41467-017-00483-x.

5.

RCC2 is a novel p53 target in suppressing metastasis.

Song C, Liang L, Jin Y, Li Y, Liu Y, Guo L, Wu C, Yun CH, Yin Y.

Oncogene. 2018 Jan 4;37(1):8-17. doi: 10.1038/onc.2017.306. Epub 2017 Sep 4.

6.

Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.

Tokheim C, Bhattacharya R, Niknafs N, Gygax DM, Kim R, Ryan M, Masica DL, Karchin R.

Cancer Res. 2016 Jul 1;76(13):3719-31. doi: 10.1158/0008-5472.CAN-15-3190. Epub 2016 Apr 28.

7.

Lamellipodia are crucial for haptotactic sensing and response.

King SJ, Asokan SB, Haynes EM, Zimmerman SP, Rotty JD, Alb JG Jr, Tagliatela A, Blake DR, Lebedeva IP, Marston D, Johnson HE, Parsons M, Sharpless NE, Kuhlman B, Haugh JM, Bear JE.

J Cell Sci. 2016 Jun 15;129(12):2329-42. doi: 10.1242/jcs.184507. Epub 2016 May 12.

8.

Deregulation of Rho GTPases in cancer.

Porter AP, Papaioannou A, Malliri A.

Small GTPases. 2016 Jul 2;7(3):123-38. doi: 10.1080/21541248.2016.1173767. Epub 2016 Apr 22. Review.

9.

Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.

Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.

10.

The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells.

Revach OY, Winograd-Katz SE, Samuels Y, Geiger B.

Exp Cell Res. 2016 Apr 10;343(1):82-88. doi: 10.1016/j.yexcr.2016.02.003. Epub 2016 Feb 10. Review.

11.

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R.

Nat Genet. 2015 Sep;47(9):996-1002. doi: 10.1038/ng.3361. Epub 2015 Jul 27.

12.

IRGM1 enhances B16 melanoma cell metastasis through PI3K-Rac1 mediated epithelial mesenchymal transition.

Tian L, Li L, Xing W, Li R, Pei C, Dong X, Fu Y, Gu C, Guo X, Jia Y, Wang G, Wang J, Li B, Ren H, Xu H.

Sci Rep. 2015 Jul 23;5:12357. doi: 10.1038/srep12357.

13.

RAC1 P29S regulates PD-L1 expression in melanoma.

Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE.

Pigment Cell Melanoma Res. 2015 Sep;28(5):590-8. doi: 10.1111/pcmr.12392.

14.

The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment.

Pajic M, Herrmann D, Vennin C, Conway JR, Chin VT, Johnsson AK, Welch HC, Timpson P.

Small GTPases. 2015;6(2):123-33. doi: 10.4161/21541248.2014.973749. Epub 2015 Jun 23. Review.

15.

Approaches of targeting Rho GTPases in cancer drug discovery.

Lin Y, Zheng Y.

Expert Opin Drug Discov. 2015;10(9):991-1010. doi: 10.1517/17460441.2015.1058775. Epub 2015 Jun 18. Review.

16.

RAC1 and melanoma.

Halaban R.

Clin Ther. 2015 Mar 1;37(3):682-5. doi: 10.1016/j.clinthera.2014.10.027. Epub 2014 Nov 22.

17.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

18.

Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Prudnikova TY, Rawat SJ, Chernoff J.

Clin Cancer Res. 2015 Jan 1;21(1):24-9. doi: 10.1158/1078-0432.CCR-14-0827. Epub 2014 Oct 21. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1772.

19.

Redox regulation of Rac1 by thiol oxidation.

Hobbs GA, Mitchell LE, Arrington ME, Gunawardena HP, DeCristo MJ, Loeser RF, Chen X, Cox AD, Campbell SL.

Free Radic Biol Med. 2015 Feb;79:237-50. doi: 10.1016/j.freeradbiomed.2014.09.027. Epub 2014 Oct 5.

20.

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L.

Cancer Res. 2014 Sep 1;74(17):4845-4852. doi: 10.1158/0008-5472.CAN-14-1232-T. Epub 2014 Jul 23.

Supplemental Content

Support Center